Junshi Biosciences' JS005 meets primary endpoints for psoriasis treatment

Shanghai Junshi Biosciences Co., Ltd. has successfully completed its phase 3 clinical study for JS005, an anti-IL-17A monoclonal antibody designed to treat moderate to severe plaque psoriasis. The study met both its co-primary and key secondary endpoints, demonstrating statistically significant and clinically meaningful improvements. The company plans to submit a new drug application to regulatory authorities soon.

The multi-center, randomized, double-blind, parallel, placebo-controlled pivotal registrational study was conducted across 60 clinical sites in China, led by professor Zhang Jianzhong. Its primary objective was to assess if participants in the JS005 group achieved at least a 90% improvement in Psoriasis Area and Severity Index (PASI 90) and a static Physician Global Assessment (sPGA) score of 0 or 1 at week 12, both superior to the placebo group.

JS005 significantly improved the area and severity of psoriasis lesions and demonstrated good safety. Psoriasis, a chronic autoimmune disease affecting approximately 125m people globally, is associated with various systemic abnormalities and significantly impacts patients' physical and mental health.